NASDAQ · INBX
Inhibrx Biosciences Inc.
$70.50-$3.15 (-4.27%)
Inhibrx Biosciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 54.57% below the high.
Loading market information…
NASDAQ · CRGX · USD
Stock price, earnings
Quote as of Aug 19, 2025, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
CARGO Therapeutics, Inc. Common Stock’s quoted price sits in the lower half of its reported 52-week range, 82.44% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Upcoming dates and analyst estimates may change. Fiscal quarters follow CARGO Therapeutics, Inc. Common Stock’s reporting calendar.
THE COMPANY BEHIND THE TICKER
CARGO Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to pioneering innovative chimeric antigen receptor (CAR) T-cell therapies for patients battling cancer. Its primary therapeutic candidate is CRG-022, an autologous CD22 CAR T-cell product. This therapy is specifically engineered to counteract mechanisms of resistance in B-cell malignancies by targeting CD22, a distinct tumor antigen prevalent in these conditions. The company's pipeline also includes CRG-023, a novel tri-specific CAR T product candidate designed to engage tumor cells through three different B-cell antigen targets. Formerly known as Syncopation Life Sciences, Inc., the company adopted its current name, CARGO Therapeutics, Inc., in September 2022. Established in 2019, CARGO Therapeutics is headquartered in San Mateo, California.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:21 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q3 2023 | Dec 13, 2023 | -$47.37-1,603.96% vs estimate | $0.00 |
|---|
THE ANALYST VIEW
7 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$70.50-$3.15 (-4.27%)
Inhibrx Biosciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 54.57% below the high.
$10.20-$0.16 (-1.53%)
Zevra Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 32.2% below the high.
$2.27$0.00 (0.0%)
Acelyrin, Inc.’s quoted price sits in the lower half of its reported 52-week range, 68.69% below the high.
$3.17-$0.25 (-7.31%)
Cytocom, Inc.’s quoted price sits in the lower half of its reported 52-week range, 9.43% below the high.
$15.15+$0.02 (+0.1%)
Merrimack Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 4.69% below the high.
$1.03-$0.01 (-0.49%)
Spectrum Pharmaceuticals, Inc.’s quoted price sits in the upper half of its reported 52-week range, 34.71% below the high.
$5.00+$0.51 (+11.36%)
Vaccitech plc’s quoted price sits in the upper half of its reported 52-week range, 1.96% below the high.
$3.31-$0.18 (-5.29%)
LENZ Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 89.65% below the high.
